US based leading edge IHC/ISH company with international distribution in 60 countries has 6 patents granted with several more pending. In addition, they have exclusive licenses important to the industry. The company focus is on difficult and tissue-based complex cancer diagnosis.The company had $34 million in 2014 revenue and EBITDA of $7M in spite of $5.5M in R&D expenditures. 2015 revenue projections are $40 plus million with EBITDA in excess of 25%.
Owners will consider a long term transition period for purchaser.
NDA required for Confidential Management Presentation.
For information please contact:
Fred AtwoodSunbelt Business AdvisorsPhone: 847.605.1510 x231 Cell: 847.293.7063Email: [email protected]
0
0
0
0
0